References
- 1. Nathan C. Specifity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling. J. Clin. Invest. 2003; 111: 769-778, DOI 10.1172/JCI200318174;10.1172/JCI200318174
- 2. Bartosz G. Druga twarz tlenu. Wolne rodniki w przyrodzie. Wyd. 2 zm. Warszawa: Wydawnictwo Naukowe PWN 2004. Polish [Second face of oxygen. Free radical in nature];
- 3. Ponczek M.B., Wachowicz B.: Oddziaływanie reaktywnych form tlenu i azotu z białkami. Post. Biochem. 2004; 51: 140–145. Polish [Interaction of reactive oxygen and nitrogen species with proteins];
- 4. Cadenas E. Mitochondrial free radical production and cell signaling. Mol Aspects Med.2004; 25: 17-26, DOI 10.1016/j.mam.2004.02.005;10.1016/j.mam.2004.02.005
- 5. Dröge W. Free radicals in the physiology control of cell function. Physiol. Rev. 2002; 82: 47-95, DOI 10.1152/physrev.00018.2001;10.1152/physrev.00018.2001
- 6. Das KC, White CW. Redox system of the cell: possible links and implications. Proc. Nat. Acad. Sci. USA. 2002; 99:9617-9618, DOI 10.1073/pnas.162369199;10.1073/pnas.162369199
- 7. Pratico D. Alzheimer’s disease and oxygen radicals: new insights. Biochem. Pharmacol. 2002; 63: 563-567, DOI 10.1016/S0006-2952(01)00919-4;10.1016/S0006-2952(01)00919-4
- 8. Perry G, Nunomura A, Hirai K, Znu X, Perez M, Avila J et al. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer’s and other neurodegenerative diseases? Free radic Biol Med 2002; 33: 1475-1479, DOI 10.1016/S0891-5849(02)01113-9;10.1016/S0891-5849(02)01113-9
- 9. Marnett LJ, Riggins JN, West JD. Endogenous generation of reactive oxidants and electrophiles, and their reactions with DNA and protein. I. Clin. Invest.2003; 111: 583-593, DOI: 10.1172/JCI200318022;
- 10. Valko M, Leibfritz D, Mancol J, Cronin MTD, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol.2007; 39: 44-84, DOI 10.1016/j.biocel.2006.07.001;10.1016/j.biocel.2006.07.001
- 11. Zabłocka A, Janusz M. Dwa oblicza wolnych rodników tlenowych. Post Hig Med. Dosw.2008; 62: 118-124, Polish [The two faces of reactive oxygen species];
- 12. Karpińska A., Gromadzka G. Stres oksydacyjny I naturalne mechanizmy antyoksydacyjne-znaczenie w procesie neurodegeneracji. Od mechanizmów molekularnych do strategii terapeutycznych. Post Hig Med Dosw 2013; 67:43-53, Polish [Oxidative stress and natural antioxidant mechanisms: the role in neurodegeneration. From molecular mechanisms to therapeutic strategies];10.5604/17322693.1029530
- 13. Gutowicz M. Wpływ reaktywnych form tlenu na ośrodkowy układ nerwowy. Post Hig Med Dosw 2011; 65: 104-113, Polish [The influence of reactive oxygen species on the central nervous system];10.5604/17322693.933486
- 14. Fang YZ, Yang S, Wu G. Free radical, antioxidants and nutrition. Nutrition 2002; 18:872-879, DOI: 10.1016/S0899-9007(02)00916-4;
- 15. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J. Neurochem. 2006; 97:1634-1658, DOI: 10.1111/j.1471-4159.2006.03907.x;
- 16. Pastore A, Federici G, Bertini E, Piemonte F. Analysis of glutathione: implication in redox and detoxification. Clin. Chim. Acta. 2003; 333:19-39, DOI 10.1016/S0009-8981(03)00200-6;10.1016/S0009-8981(03)00200-6
- 17. Kehrer JP, Klotz LO. Free radicals and related reactive species as mediators of tissue injury and disease: implications for Health. Crit Rev Toxicol. 2015; 45(9):765-98. DOI 10.3109/10408444.2015.1074159;10.3109/10408444.2015.107415926610815
- 18. Gregório BM, De Souza DB, de Morais Nascimento FA, Pereira LM, Fernandes-Santos C. The potential role of antioxidants in metabolic syndrome. Curr Pharm Des. 2015; 22: 859 - 869 DOI 10.2174/1381612822666151209152352;10.2174/138161282266615120915235226648468
- 19. Goszcz K, Deakin SJ, Duthie GG, Stewart D, Leslie SJ, Megson IL. Antioxidants in Cardiovascular Therapy: Panacea or False Hope? Front Cardiovasc Med. 2015; 2:29. DOI 10.3389/fcvm.2015.00029;10.3389/fcvm.2015.00029467134426664900
- 20. Simone CB, Simone NL, Simone V, Simone CB. Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1. Altern Ther Health Med. 2007;13(1):22-28;
- 21. Miyanishi K, Hoki T, Tanaka S, Kato J. Prevention of hepatocellular carcinoma: Focusing on antioxidant therapy. World J Hepatol. 2015; 7(3):593-9. doi: 10.4254/wjh.v7.i3.593;
- 22. Martinez-Outschoorn UE, Balliet R, Lin Z, Whitaker-Menezes D, Birbe RC, Bombonati A, et al.. BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies. Cell Cycle. 2012; 11(23):4402-13. doi: 10.4161/cc.22776;
- 23. Wambi C, Sanzari J, Wan XS, Nuth M, Davis J, Ko YH, et al. Dietary Antioxidants Protect Hematopoietic Cells and Improve Animal Survival after Total-Body Irradiation. Radiat Res. 2008; 169(4): 384–396, DOI 10.1667/RR1204.1;10.1667/RR1204.1269223618363433
- 24. Brown SL, Kolozsvary A, Liu J, Jenrow KA, Ryu S, Kim JH. Antioxidant Diet Supplementation Starting 24 Hours after Exposure Reduces Radiation Lethality. Radiat Res. 2010; 173(4): 462–468, DOI 10.1667/RR1716.1;10.1667/RR1716.1287493420334518
- 25. Rafieian-Kopaie M, Nasri H. On the Occasion of World Cancer Day 2015; the Possibility of Cancer Prevention or Treatment with Antioxidants: The Ongoing Cancer Prevention Researches. Int J Prev Med. 2015; 6: 108, DOI 10.4103/2008-7802.169077;10.4103/2008-7802.169077467117526644907
- 26. Reliene R, Schiestl RH. Experimental antioxidant therapy in ataxia telangiectasia. Clin Med Oncol. 2008; 2:431-436;10.4137/CMO.S535316169521892312
- 27. Reichenbach J, Schubert R, Schwan C, Müller K, Böhles HJ, Zielen S. Anti-oxidative capacity in patients with ataxia telangiectasia. Clin Exp Immunol. 1999; 117(3): 535–539, DOI 10.1046/j.1365-2249.1999.01000.x;10.1046/j.1365-2249.1999.01000.x190535810469059
- 28. Peyser CE, Folstein M, Chase GA, Starkstein S, Brandt J, Cockrell JR, et al. Trial of d-alpha-tocopherol in Huntington’s disease. Am J Psychiatry. 1995; 152(12):1771-5, DOI 10.1176/ajp.152.12.1771;10.1176/ajp.152.12.17718526244
- 29. Jin H, Kanthasamy A, Ghosh A, Anantharam V, Kalyanaraman B, Kanthasamy AG. Mitochondria-targeted antioxidants for treatment of Parkinson’s disease: preclinical and clinical outcomes. Biochim Biophys Acta. 2014; 1842(8): 1282–1294, DOI 10.1016/j.bbadis.2013.09.007;10.1016/j.bbadis.2013.09.007396156124060637
- 30. Underwood BR, Imarisio S, Fleming A, Rose C, Krishna G, Heard P, et al. Antioxidants can inhibit basal autophagy and enhance neurodegeneration in models of polyglutamine disease. Hum Mol Genet. 2010; 19(17): 3413–3429, DOI 10.1093/hmg/ddq253;10.1093/hmg/ddq253291670920566712
- 31. Mut-Salud N, Álvarez PJ, Garrido JM, Carrasco E, Aránega A, Rodríguez-Serrano F. Antioxidant Intake and Antitumor Therapy: Toward Nutritional Recommendations for Optimal Results. Med Cell Longev. 2016; 2016: 6719534, DOI 10.1155/2016/6719534.